Therapeutic drug monitoring of mycophenolate mofetil and enteric-coated mycophenolate sodium in patients with systemic lupus erythematosus

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 5, 2010, Pages 689-699

  Djabarouti, Sarah ^a   Duffau, Pierre ^a   Lazaro, Estibaliz ^a   Chapouly, Candice ^a   Greib, Carine ^a   Viallard, Jean François ^a   Pellegrin, Jean Luc ^a   Saux, Marie Claude ^a   Breilh, Dominique ^a  

^a BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

Enteric coated mycophenolate sodium; Limited sampling strategy; Mycophenolate mofetil; Pharmacokinetics; Systemic lupus erythematosus

Indexed keywords

CALCITRIOL; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTON PUMP INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG MONITORING; ENTERIC COATED TABLET; FEMALE; HUMAN; KIDNEY FUNCTION; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; OSTEOPOROSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME TO MAXIMUM PLASMA CONCENTRATION; ULCER;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; DRUG MONITORING; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; TABLETS, ENTERIC-COATED; TIME FACTORS;

EID: 77949454177     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656561003592144     Document Type: Article

References (30)

1. Nannini C, Crowson C, Matteson E, Moder KG. Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus. Lupus 2009;18:94-99
2. Posalski J, Ishimori M, Wallace DJ, Weisamn M. Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years. Lupus 2009;18:516-521
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007;46:13-58
4. Budde K, Glander P, Diekmann F, et al. Review of the immunosuppressant enteric-coated mycophenolate sodium. Expert Opin Pharmacother 2004;5:1333-1345
5. Arns W, Breuer S, Choudhury S, et al. Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil. Clin Transplant 2005;19:199-206
6. Le Meur Y, Büchler M, Thierry A, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcome after renal transplantation. Am J Transplant 2007;7:2496-2503
7. Barraclough KA, Staatz CE, Isbel NM, Johnson DW. Therapeutic monitoring of mycophenolate in transplantation: is it justified? Curr Drug Metab 2009;10:179-187
8. Cooper M, Deering KL, Slakey DP, et al. Comparing outcomes associated with dose manipulations of enteric-coated mycophenolate sodium versus mycophenolate mofetil in renal transplant recipients. Transplantation 2009;88:514-520
9. Cattaneo D, Merlini S, Zenoni S, et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005;5:2937-2944
10. Neumann I, Haidinger M, Jager H, et al. Pharmacokinetics of mycophenolate mofetil in patients with autoimmune diseases compared to renal transplant recipients. J Am Soc Nephrol 2003;14:721-727
11. Czock D, Rasche FM, Carius A, et al. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate sodium versus mycophenolate mofetil in patients with progressive IgA nephritis. J Clin Pharmacol 2007;47:850-859
12. Roland M, Barbet C, Paintaud G, et al. Mycophenolate mofetil in patients with systemic lupus erythematosus: a prospective pharmacokinetic study. Lupus 2009;18:441-447
13. Zahr N, Amoura Z, Debord J, et al. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies. Clin Pharmacokinet 2008;47:277-284
14. Neumann I, Fuhrman H, Fang IF, et al. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune diseases on mycophenolate mofetil. Nephrol Dial Transplant 2008;23:3514-3520
15. Filler G, Lathia A, LeBlanc C, Christians U. Unexpectedly high exposure to enteric-coated mycophenolate sodium upon once-daily dosing. Pediatr Nephrol 2006;21:1206-1208
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
17. Djabarouti S, Duffau P, Xuereb F, et al. Measurement of total and unbound mycophenolic acid and its glucuronide by liquid chromatography coupled with mass spectrometry. Application to pharmacokinetic study of mycophenolate mofetil in patients with autoimmune diseases. Chromatographia 2009;70:939-945
18. Mathew BS, Fleming DH, Jeyaseelan V, et al. A limited sampling strategy for tacrolimus in renal transplant recipients. Br J 1Clin Pharmacol 2008;66:467-472
19. Wong KM, Shek CC, Chau KF, Li CS. Abbreviated tacrolimus area under the curve monitoring for renal transplant recipients. Am J Kidney Dis 2000;35:660-666
20. Mohammadpour AH, Nazemian B, Abtahi B, et al. Estimation of abbreviated mycophenolic acid area under the concentration-time curve during early posttransplant period by limited sampling strategy. Transplant Proc 2008;40:3668-3672
21. Pawinski T, Kunicki PK, Sobieszczanska-Malek M, et al. A limited sampling strategy for estimating mycophenolic acid area under the curve in adult heart transplant patients treated with concomitant cyclosporine. J Clin Pharm Ther 2008;34:89-101
22. Krouwer JS. Why Bland-Altman plots should use X, not (Y+X)/2 when X is a reference method. Stat Med 2008;27:778-780
23. Neumann I, Fuhrmann H, Kanzler M, et al. Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft. Expert Opin Pharmacother 2008;9:879-886
24. Perry TW, Christians U, Trotter JF, et al. Pharmacokinetics of enteric-coated mycophenolate sodium in stable liver transplant recipients. Clin Transplant 2007;21:413-416
25. Hummel M, Yonan N, Ross H, et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant 2007;21:18-23
26. de Winter BC, van Gelder T, Glander P, et al. Population pharmacokinetics of mycophenolic acid: a comparison between enteric-coated mycophenolate sodium and mycophenolate mofetil in renal transplant recipients. Clin Pharmacokinet 2008;47:827-838
27. Cattaneo D, Cortinovis M, Baldelli S, et al. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Clin J Am Soc Nephrol 2007;2:1147-1155
28. Bullingham R, Shah J, Goldblum R, Schiff M. Effects of food and antiacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients. Br J Clin Pharmacol 1996;41:513-516
29. de Winter BC, van Gelder T, Mathot RA, et al. Limited sampling strategies drawn within 3 hours postdose poorly predict mycophenolic acid area-under-the-curve after enteric-coated mycophenolate sodium. Ther Drug Monit 2009;31:585-591
30. Filler G, Hansen M, LeBlanc C, et al. Pharmacokinetics of mycophenolate mofetil for autoimmune disease in children. Pediatr Nephrol 2003;18:445-449